Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Gains from Sales and Divestitures: 2023-2024

Historic Gains from Sales and Divestitures for SAB Biotherapeutics (SABS) over the last 2 years, with Dec 2024 value amounting to $22,709.

  • SAB Biotherapeutics' Gains from Sales and Divestitures fell 59.98% to $12,544 in Q3 2025 from the same period last year, while for Sep 2025 it was $12,544, marking a year-over-year decrease of 59.98%. This contributed to the annual value of $22,709 for FY2024, which is 77.19% up from last year.
  • SAB Biotherapeutics' Gains from Sales and Divestitures amounted to $22,709 in FY2024, which was up 77.19% from $12,816 recorded in FY2023.
  • Over the past 5 years, SAB Biotherapeutics' Gains from Sales and Divestitures peaked at $22,709 during FY2024, and registered a low of $12,816 during FY2023.
  • Its 2-year average for Gains from Sales and Divestitures is $17,762, with a median of $17,762 in 2023.
  • Data for SAB Biotherapeutics' Gains from Sales and Divestitures shows a peak YoY surged of 77.19% (in 2024) over the last 5 years.
  • Over the past 2 years, SAB Biotherapeutics' Gains from Sales and Divestitures (Yearly) stood at $12,816 in 2023, then soared by 77.19% to $22,709 in 2024.